Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

2012212 citationsJournal Article

Authors

Richard S. Finn · Bristol-Myers Squibb (South Korea)

Yoon‐Koo Kang · National Cancer Center

Mary F. Mulcahy · Bristol-Myers Squibb (Belgium)

Blasé N. Polite · University of Chicago Medical Center

Ho Yeong Lim · Samsung Medical Center

Ian Walters · Asan Medical Center

Christine Baudelet

Abstract

Brivanib had a manageable safety profile and is one of the first agents to show promising antitumor activity in advanced HCC patients treated with prior sorafenib.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Liver physiology and pathology Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 18, Issue 7, pp. 2090-2098

DOI: 10.1158/1078-0432.ccr-11-1991

Field-Weighted Citation Impact: 20.49